Repletion of testosterone (Te) in older men drives GH secretion after its aromatization to estradiol (E2), which acts via the estrogen receptor (ER). Conversely, we postulate that estrogen deprivation in postmenopausal women attenuates growth hormone (GH) secretion and insulin-like growth factor-1 (IGF-I) production, thus favoring development of metabolic syndrome in men treated with toremifene, a new estrogen antagonist used adjunctively in prostatic cancer

Start Date01 Dec 2014

Sponsor / Collaborator

Mayo Clinic

100 Clinical Results associated with Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.)

100 Translational Medicine associated with Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.)

100 Patents (Medical) associated with Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.)

1,241

Literatures (Medical) associated with Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.)

01 Jan 2024·Cytokine

Growth hormone-releasing hormone antagonists counteract interferon-γ – induced barrier dysfunction in bovine and human endothelial cells

Article

Author: Barabutis, Nektarios ; Fakir, Saikat

GHRH regulates the secretion of GH from the anterior pituitary gland. An emerging body of evidence suggests that the activities of that neuropeptide are not limited to the GH/IGF-I axis, but they expand towards the mediation of inflammatory processes. GHRHAnt were developed to oppose the activities of GHRH in malignancies, and have been associated with strong anti-inflammatory and anti-oxidative effects in a diverse variety of tissues, including the lungs. In the present study we report that GHRHAnt oppose interferon-γ - induced paracellular hyperpermeability and reactive oxygen species generation in bovine and human pulmonary endothelial cells; and suppress interferon-γ - triggered STAT3, cofilin and ERK1/2 activation. Our observations substantiate previous findings on the protective effects of GHRHAnt in endothelial inflammation and barrier break-down.

01 Dec 2023·Analytical biochemistry

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Article

Author: David, Victor ; Cristea, Cătălina-Diana ; Radu, Mihai ; Toboc, Ani ; Stan, Cristina

The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). Considering the complexity of urine samples and the low concentrations at which these analytes should be detected, analyzing GHRHs is a challenging task. In most of the studies, GHRHs are analyzed using UHPLC-HRMS with an orbitrap. The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH₂, somatorelin) is based on the triple quadrupole UHPLC/MS-MS method with solid phase extraction (SPE) with weak cation exchange and is able to detect concentrations as low as 0.2 ng/mL (LOD), a limit of quantification (LOQ) at 0.6 ng/mL, and linearity across the range of 0.1 ng/mL to 1.2 ng/mL. The present method developed by our doping control laboratory was validated according to WADA technical documents for selectivity, limit of detection (LOD), carryover, reliability of detection, stability and recovery. The results show that the method has adequate recoveries and sensitivity, hence, it can be employed for routine screening in anti-doping laboratories.

01 Oct 2023·Journal of endocrinological investigation

GHRH + arginine test and body mass index: do we need to review diagnostic criteria for GH deficiency

Article

Author: Varaldo, E. ; Gasco, V. ; Ghigo, E. ; Bioletto, F. ; Grottoli, S. ; Bona, C. ; Berton, A. M. ; Prencipe, N. ; Maccario, M. ; Cuboni, D.

INTRODUCTIONThe proportion of patients with low GH response to provocative tests increases with the number of other pituitary hormone deficiencies, reason why in panhypopituitary patients GH stimulation tests may be unnecessary to diagnose GH deficiency (GHD) PURPOSE: To re-evaluate the diagnostic cut-offs of GH response to GHRH + arginine (ARG) test related to BMI, considering the patients' pituitary function as the gold standard for the diagnosis of GHD.METHODSThe GH responses to GHRH + ARG were studied in 358 patients with history of hypothalamic-pituitary disease. GHD was defined by the presence of at least 3 other pituitary deficits (n = 223), while a preserved somatotropic function was defined by the lack of other pituitary deficits and an IGF-I SDS ≥ 0 (n = 135). The cut-off with the best sensitivity (SE) and specificity (SP), was identified for each BMI category using the ROC curve analysis. To avoid over-diagnosis of GHD we subsequently searched for the cut-offs with a SP ≥ 95%.RESULTSThe best GH cut-off was 8.0 μg/l (SE 95%, SP 100%) in lean, 7.0 μg/l (SE 97.3%, SP 82.8%) in overweight, and 2.8 μg/l (SE 84.3%, SP 91.7%) in obese subjects. The cut-off with a SP ≥ 95% was 2.6 μg/l (SE 68.5%, SP 96.6%) in overweight and 1.75 μg/l (SE 70.0%, SP 97.2%) in obese subjects.CONCLUSIONSThis is the first study that evaluates the diagnostic cut-offs of GH response to GHRH + ARG related to BMI using a clinical definition of GHD as gold standard. Our results suggest that with this new approach, the GHRH + ARG cut-offs should be revised to avoid GHD over-diagnosis.

100 Deals associated with Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Truncated somatorelin(Fujisawa Pharmaceutical Co., Ltd.)	V04CD05	DB12656

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Growth hormone deficiency	Phase 3	-	Fujisawa Pharmaceutical Co., Ltd.	-
Growth hormone deficiency	Phase 3	United States	-	-
Growth hormone deficiency	Phase 3	-	Bausch Health Americas, Inc.	-
Growth hormone deficiency	Phase 3	-	Bausch Health Americas, Inc.	-
Growth hormone deficiency	Phase 3	-	Fujisawa Pharmaceutical Co., Ltd.	-
Growth hormone deficiency	Phase 3	United States	-	-
Muscular Atrophy	Phase 3	Switzerland	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESPE2014	Not Applicable	Prader-Willi Syndrome GH peak \| IGF1 levels	28	GHRH+pyridostigmine	hprclvwlvm(sdrkkslsmd) = befycbplzn tuelzslljt (peapoqrrwq )	-	18 Sep 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis